当前位置： SCI文献检索 > CARDIOVASCULAR DRUGS AND THERAPY期刊下所有文献 > Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle.

Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle.

Abstract：

:The effects of altered extracellular K+ concentrations ([K+]o) and pacing cycle lengths (CLs) on the electrophysiological actions of dofetilide (UK-68,798), a potent class III antiarrhythmic agent, were examined in isolated guinea-pig ventricular papillary muscle. At a normal [K+]o (4 mM) and at CL between 300 and 5000 msec, dofetilide (10 nM) significantly increased the action-potential duration (APD) and the effective refractory period (ERP), whereas other action-potential parameters were unaffected. Elevation of [K+]o to 10 mM reduced membrane diastolic potential (MDP), action-potential amplitude (APA), and the maximum rising velocity of the action-potential upstroke (Vmax). These changes were accompanied by a small shortening of APD90, but with an increase in ERP; i.e., the ERP/APD90 ratio was increased. Dofetilide also significantly lengthened APD90 at 10 mM [K+]o and at each CL. Even at the short cycle lengths (300 and 500 msec), dofetilide-induced increases in APD90 were not attenuated whether [K+]o was at 4 or 10 mM. These results indicate that at various pacing CLs, 10 nM dofetilide increases myocardial APD and ERP to a similar extent without significant reverse use-dependence when the cell membrane is normally polarized or partially depolarized by elevated [K+]o. Dofetilide may, therefore, be expected to be beneficial in the treatment of cardiac tachyarrhythmias related or unrelated to regional myocardial hyperkalemia during myocardial ischemia.

journal_name

Cardiovasc Drugs Ther

journal_title

Cardiovascular drugs and therapy

authors

Yang T,Tande PM,Lathrop DA,Refsum H

doi

10.1007/BF00054193

subject

Has Abstract

pub_date

1992-08-01 00:00:00

pages

429-36

issue

4

eissn

0920-3206

issn

1573-7241

journal_volume

6

pub_type

杂志文章

相关文献

CARDIOVASCULAR DRUGS AND THERAPY文献大全
  • Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

    abstract：:The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,已发布勘误

    doi：10.1007/s10557-018-6834-6

    authors： Ahn R,Prasad V

    更新日期：2018-12-01 00:00:00

  • Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers.

    abstract：:Nicorandil (N) and isosorbide dinitrate (ISDN) are vasodilator drugs used in patients with angina. In 24 healthy male volunteers (18-32 years), the acute effect of a single oral dose (20 mg) of N and ISDN on arterial diameter (D), distensibility, and compliance of the elastic common carotid artery (CCA) and the muscul...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00878678

    authors： Kool MJ,Spek JJ,Struyker Boudier HA,Hoeks AP,Reneman RS,van Herwaarden RH,Van Bortel LM

    更新日期：1995-04-01 00:00:00

  • The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

    abstract：:Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF03029726

    authors： Fitzgerald JD

    更新日期：1991-06-01 00:00:00

  • Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial.

    abstract：:Quality of life in heart failure patients is receiving increased attention as a reflection of a treatment's potential secondary benefit of general well-being and daily functioning. The Metoprolol in Dilated Cardiomyopathy (MDC) trial was conducted as a large, multicenter trial to establish the effects of metoprolol on...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF02627961

    authors： Wiklund I,Waagstein F,Swedberg K,Hjalmarsson A

    更新日期：1996-07-01 00:00:00

  • Changes in urinary enzyme levels following the use of antihypertensive agents in patients with essential hypertension.

    abstract：:When choosing antihypertensive agents for the treatment of hypertension, it is necessary to consider the predisposition of individuals to renal damage, which may be associated with the long-term effect of such agents. In this respect, this study examined the effect of two commonly used antihypertensive drugs (Brinerdi...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00879029

    authors： Obatomi DK,Mogbo SC,Anjorin FI,Jigam AA

    更新日期：1995-06-01 00:00:00

  • The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species.

    abstract：PURPOSE:The melatonin receptor (MT) agonist ramelteon has a higher affinity to MT1 than for MT2 receptors and induces cardioprotection by involvement of mitochondrial potassium channels. Activation of mitochondrial potassium channels leads to release of free radicals. We investigated whether (1) ramelteon-induced cardi...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-06972-4

    authors： Stroethoff M,Goetze L,Torregroza C,Bunte S,Raupach A,Heinen A,Mathes A,Hollmann MW,Huhn R

    更新日期：2020-06-01 00:00:00

  • Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.

    abstract：:Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at a...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s10557-015-6637-y

    authors： Dubé MP,de Denus S,Tardif JC

    更新日期：2016-02-01 00:00:00

  • Racial differences in antihypertensive therapy: evidence and implications.

    abstract：:Blood pressure is controlled by many factors, and thus hypertension is a multifactorial disorder. This etiologic diversity is also reflected in the broad spectrum of different pharmacologic agents known to lower blood pressure. Most carefully controlled studies employing a single antihypertensive drug in unselected, u...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF02603180

    authors： Weinberger MH

    更新日期：1990-03-01 00:00:00

  • How do calcium antagonists differ in clinical practice?

    abstract：:The majority of calcium antagonists used clinically belong to three distinct chemical classes: the phenylalkylamines, the dihydropyridines, and the benzothiazepines. In recent years their mode of action has been unravelled, their limitations recognized, and their efficacy and use in the management of patients with a b...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00877225

    authors： Ferrari R,Cucchini F,Bolognesi R,Bachetti T,Boraso A,Bernocchi P,Gaia G,Visioli O

    更新日期：1994-08-01 00:00:00

  • Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy.

    abstract：PURPOSE:To assess the effects of electro-acupuncture (EA) on glycemic control, myocardial inflammation, and the progression of diabetic cardiomyopathy in mice with type 2 diabetes. METHODS:Db/Db mice received EA at PC6+ST36 (DM-Acu), non-acupoint simulation (DM-Sham), or no treatment (DM). EA was applied for 30 min pe...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07043-4

    authors： Ye Y,Birnbaum Y,Widen SG,Zhang Z,Zhu S,Bajaj M,Chen H

    更新日期：2020-12-01 00:00:00

  • Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris.

    abstract：:This study was designed to compare once-daily administration of 5-10 mg amlodipine with two daily doses of 40 mg sustained-release isosorbide dinitrate in 59 patients with stable angina using a randomized, double-blind, crossover study design. Anginal episodes, nitroglycerin consumption, and possible adverse events we...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1007726722284

    authors： Steffensen R,Melchior T,Bech J,Nissen H,Haastrup B,Grande P,Rasmussen V,Hansen JF,Skagen K,Haghfelt T

    更新日期：1997-11-01 00:00:00

  • Fish oil and the prevention and regression of atherosclerosis.

    abstract：:Epidemiological studies in the seventies have put forward that dietary rather than genetic factors are responsible for the lower incidence of ischemic heart disease in Greenland Inuit and have generated a large body of both in vitro and in vivo experimental studies, exploring the putative favorable effects of fish (oi...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00877326

    authors： Sassen LM,Lamers JM,Verdouw PD

    更新日期：1994-04-01 00:00:00

  • Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.

    abstract：:The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of lef...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1007713118941

    authors： Sheiban I,Tonni S,Chizzoni A,Marini A,Trevi G

    更新日期：1997-03-01 00:00:00

  • Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.

    abstract：PURPOSE:In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adul...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10557-014-6516-y

    authors： Rosenson RS,Rigby SP,Jones MR,Chou HS

    更新日期：2014-06-01 00:00:00

  • The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication).

    abstract：:Chronic renal failure (CRF) patients with a stable course were asked to participate in a follow-up program in which they were randomized into two groups: 1) the placebo group taking their standard antihypertensive therapy without any calcium ion blocker: and 2) the nisoldipine group, those patients taking the calcium ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF02125735

    authors： Eliahou HE,Cohen D,Ben-David A,Herzog D,Serban I,Gavendo S,Kapuler S,Kogan N,Hellberg B

    更新日期：1988-01-01 00:00:00

  • Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts.

    abstract：:Amlodipine increases NO levels in coronary vessels and aorta via bradykinin-dependent mechanisms in vitro. We have previously reported that a long-acting Ca channel blocker, benidipine, increases cardiac NO levels in ischemic canine hearts, suggesting that benidipine may also protect against ischemia and reperfusion i...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1011964222712

    authors： Asanuma H,Kitakaze M,Node K,Takashima S,Sakata Y,Asakura M,Sanada S,Shinozaki Y,Mori H,Tada M,Kuzuya T,Hori M

    更新日期：2001-01-01 00:00:00

  • Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.

    abstract：BACKGROUND:Recent studies in rabbits have demonstrated that platelet P2Y12 receptor antagonists are cardioprotective, and that the mechanism is surprisingly not related to blockade of platelet aggregation but rather to triggering of the same signal transduction pathway seen in pre- and postconditioning. We wanted to de...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-012-6436-7

    authors： Yang XM,Liu Y,Cui L,Yang X,Liu Y,Tandon N,Kambayashi J,Downey JM,Cohen MV

    更新日期：2013-04-01 00:00:00

  • Left ventricular mass changes with nicardipine therapy in essential hypertension.

    abstract：:Eighteen hypertensive patients (13 males, 5 females; age 48 +/- 13; diastolic blood pressure greater than 95 mmHg), either previously untreated or who had been off treatment for more than 3 months, underwent M-mode echocardiography before (DO) and after (D90) 3 months of nicardipine therapy (60-90 mg/day). All echocar...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01865511

    authors： Gosse P,Lacroix P,Roudaut R,Dallocchio M

    更新日期：1989-08-01 00:00:00

  • Central and peripheral irisin differentially regulate blood pressure.

    abstract：INTRODUCTION:Irisin is a newly identified 112 amino acid hormone, derived as a product of fibronectin type III domain containing 5 (FNDC5), which is highly related to metabolic activity in skeletal muscle and brown fat. The effects of irisin on cardiovascular functions are unknown. PURPOSE:To explore the effects of ce...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6580-y

    authors： Zhang W,Chang L,Zhang C,Zhang R,Li Z,Chai B,Li J,Chen E,Mulholland M

    更新日期：2015-04-01 00:00:00

  • Ranolazine Attenuates the Electrophysiological Effects of Myocardial Stretch in Langendorff-Perfused Rabbit Hearts.

    abstract：PURPOSE:Mechanical stretch is an arrhythmogenic factor found in situations of cardiac overload or dyssynchronic contraction. Ranolazine is an antianginal agent that inhibits the late Na (+) current and has been shown to exert a protective effect against arrhythmias. The present study aims to determine whether ranolazin...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6587-4

    authors： Chorro FJ,del Canto I,Brines L,Such-Miquel L,Calvo C,Soler C,Parra G,Zarzoso M,Trapero I,Tormos Á,Alberola A,Such L

    更新日期：2015-06-01 00:00:00

  • Therapeutic advances in heart failure.

    abstract：:Annual mortality from congestive heart failure ranges from 15% to 60%, depending on the severity of the left ventricular damage and underlying disease. Most controlled trials have been too small to detect any beneficial effect on survival from the newer vasodilator and inotropic drugs. However, the results of two rece...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Meinertz T,Drexler H,Just H

    更新日期：1988-11-01 00:00:00

  • Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.

    abstract：PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-016-6650-9

    authors： Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

    更新日期：2016-04-01 00:00:00

  • The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19.

    abstract：PURPOSE:To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. METHODS:We conducted a retrospective study of patients consecutively enrolled from two major academic hospitals exclusively for COVID-19 in Wuhan, China, from January 26, 2020, to March...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07133-3

    authors： Shen L,Qiu L,Liu D,Wang L,Huang H,Ge H,Xiao Y,Liu Y,Jin J,Liu X,Wang DW,Peterson ED,He B,Zhou N

    更新日期：2021-01-04 00:00:00

  • A systemic combination therapy with granulocyte-colony stimulating factor plus erythropoietin aggravates the healing process of balloon-injured rat carotid arteries.

    abstract：OBJECTIVE:Percutaneous vascular interventions lead inevitably to a destruction of the endothelial lining at the site of injury. There are conflicting data on the therapeutic benefit of hematopoietic growth factors aiming at mobilisation of circulating endothelial cells to accelerate the reendothelialisation process. Ai...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-008-6117-8

    authors： Hack M,Mascha FG,Jobst BJ,Riegger GA,Griese DP

    更新日期：2008-10-01 00:00:00

  • Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.

    abstract：PURPOSE:Single- and multiple-dose studies were conducted to assess the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Japanese subjects. METHODS:All studies were single-center, randomized, placebo-controlled, single-blind or double-blind. In an ascending single-dose study, subjects were given a ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10557-011-6299-3

    authors： Kim SR,Hasunuma T,Sato O,Okada T,Kondo M,Azuma J

    更新日期：2011-12-01 00:00:00

  • Unique Aspects of Coronary Artery Disease in Indian Women.

    abstract：PURPOSE:Epidemiologic and clinical research suggests important gender-related differences in the prevalence, presentation, associated conventional and non-conventional risk factors, management and outcomes of coronary heart disease (CHD) patients. Adequate data is not available for Indian population where prevalence of...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6594-5

    authors： Bhatt P,Parikh P,Patel A,Parikh R,Patel A,Mehta JL,Parikh K

    更新日期：2015-08-01 00:00:00

  • Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.

    abstract：:Pulmonary arterial hypertension (PAH) is a group of diseases characterized by a progressive increase of pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies have here confirmed the prominent role of endothelin (ET)-1 in vasoconstric...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s10557-015-6605-6

    authors： Madonna R,Cocco N,De Caterina R

    更新日期：2015-01-01 00:00:00

  • Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials.

    abstract：OBJECTIVE:This review aims at updating the results of cardiac resynchronization therapy (CRT) in mild heart failure patients, and investigating whether CRT can prevent or reverse heart failure progression in an earlier stage. METHODS:Randomized controlled trials of CRT in patients with New York Heart Association (NYHA...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10557-011-6313-9

    authors： Tu R,Zhong G,Zeng Z,Wu W,Wu H,Cao X,Aung LH

    更新日期：2011-08-01 00:00:00

  • Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial.

    abstract：PURPOSE:Morphine has been used for several decades in cases of acute pulmonary edema (APE) due to the anxiolytic and vasodilatory properties of the drug. The non-specific depression of the central nervous system is probably the most significant factor for the changes in hemodynamics in APE. Retrospective studies have s...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10557-017-6722-5

    authors： Dominguez-Rodriguez A,Burillo-Putze G,Garcia-Saiz MDM,Aldea-Perona A,Harmand MG,Mirò O,Abreu-Gonzalez P,MIMO investigators.

    更新日期：2017-04-01 00:00:00

  • Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.

    abstract：PURPOSE:Oxidative stress plays an important role in the pathogenesis of cardiovascular diseases. Azelnidipine is a novel dihydropyridine calcium channel blocker. Several studies have demonstrated that some dihydropyridine calcium channel blockers have antioxidant effects. We evaluated the antioxidant effects of azelnid...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-007-6008-4

    authors： Koyama Y,Takeishi Y,Takahashi H,Shishido T,Arimoto T,Niizeki T,Harada M,Suzuki S,Kitahara T,Sasaki T,Kubota I

    更新日期：2007-02-01 00:00:00